Senolytic treatment does not mitigate oxidative stress-induced muscle atrophy but improves muscle force generation in CuZn superoxide dismutase knockout mice

Agnieszka K. Borowik,Marcus M. Lawrence,Frederick F. Peelor,Katarzyna M. Piekarz,Abby Crosswhite,Arlan Richardson,Benjamin F. Miller,Holly Van Remmen,Jacob L. Brown

DOI: https://doi.org/10.1007/s11357-024-01070-x

2024-01-19

GeroScience

Abstract:Oxidative stress is associated with tissue dysfunctions that can lead to reduced health. Prior work has shown that oxidative stress contributes to both muscle atrophy and cellular senescence, which is a hallmark of aging that may drive in muscle atrophy and muscle contractile dysfunction. The purpose of the study was to test the hypothesis that cellular senescence contributes to muscle atrophy or weakness. To increase potential senescence in skeletal muscle, we used a model of oxidative stress-induced muscle frailty, the CuZn superoxide dismutase knockout ( Sod1 KO) mouse. We treated 6-month-old wildtype (WT) and Sod1 KO mice with either vehicle or a senolytic treatment of combined dasatinib (5 mg/kg) + quercetin (50 mg/kg) (D + Q) for 3 consecutive days every 15 days. We continued treatment for 7 months and sacrificed the mice at 13 months of age. Treatment with D + Q did not preserve muscle mass, reduce NMJ fragmentation, or alter muscle protein synthesis in Sod1 KO mice when compared to the vehicle-treated group. However, we observed an improvement in muscle-specific force generation in Sod1 KO mice treated with D + Q when compared to Sod1 KO-vehicle mice. Overall, these data suggest that reducing cellular senescence via D + Q is not sufficient to mitigate loss of muscle mass in a mouse model of oxidative stress-induced muscle frailty but may mitigate some aspects of oxidative stress-induced muscle dysfunction.

geriatrics & gerontology,gerontology